# Ecopipam Treatment of Tourette Syndrome

> **NCT01244633** · PHASE1,PHASE2 · COMPLETED · sponsor: **Psyadon Pharma** · enrollment: 18 (actual)

## Conditions studied

- Tourette's Syndrome

## Interventions

- **DRUG:** Ecopipam

## Key facts

- **NCT ID:** NCT01244633
- **Lead sponsor:** Psyadon Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-07
- **Final completion:** 2013-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244633, "Ecopipam Treatment of Tourette Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01244633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*